key: cord-0035774-sxanz2zy
authors: Rivera, Melvin J.; Do, Bryan; Bryan, Jeffrey C.; Shigle, Terri Lynn; Patel, Rina
title: Complications and Toxicities Associated with Cancer Therapies in the Intensive Care Unit
date: 2019-07-09
journal: Oncologic Critical Care
DOI: 10.1007/978-3-319-74588-6_21
sha: 1f5d6eb3cba68f2eda2f4dcd27820b75454e73c6
doc_id: 35774
cord_uid: sxanz2zy

Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. Currently, there are over 175 FDA-approved antineoplastic agents in the United States, many with a diverse and profound toxicity profile. Complications of antineoplastic therapy may result in the need for intensive care unit (ICU) admission to provide acute symptom management. Accordingly, ICU providers caring for cancer patients should have a working knowledge of the toxicities and complications associated with antineoplastic therapy.

The prevalence of cancer has grown tremendously and with that so has the need for new or repurposed anticancer therapies. Advances in the management of hematologic malignancies and solid tumors have given rise to diverse modalities to treat cancer other than cytotoxic chemotherapy, including targeted therapies, immunotherapies, and cellular therapies. There are over 175 approved antineoplastic agents in the United States and more in development with unique toxicity profiles [163] . This has created a unique opportunity for critical care specialists to manage complications of critically ill cancer patients receiving anticancer therapies.

Tables 1A-H provides a list of antineoplastic agents and toxicities that may necessitate a higher level of care and/or impact care within the intensive care unit (ICU). These tables are not all-inclusive of every minor adverse effect of each agent. Instead, they focus on toxicities that are considered severe/ life-threatening complications or clinically relevant (e.g., grade 3 or 4 adverse effects). Agents that did not meet the criteria for addition to Tables 1A-H include the following: azacitidine, cladarabine, decitabine, elotuzumab, hydroxyurea, ixazomib, lomustine, olaratumab, omacetaxine, procarbazine, talimogene, valrubicin, and venetoclax. case reports, onset 12-13 months. May aggravate underlying autoimmune disorders. Management includes holding therapy, systemic corticosteroids, +/À additional immunosuppressants (e.g., infliximab, mycophenolate, and vedolizumab). Consider PJP prophylaxis in patients with prolonged corticosteroid exposure [33, 89, 122, 160] 13 May cause severe immune-mediated adverse events including pneumonitis, median onset 2.5 months (3 days to 11 month); hepatitis, median onset 3.2 months (7 days to 15 months); colitis, median onset 2.1 months (2 days to 11 months); adrenal insufficiency, median onset 2.5 months; immune-mediated thyroid disorders, median onset for 2.8 months (2 weeks to 13 months). May aggravate underlying autoimmune disorders. Management includes holding therapy, systemic corticosteroids, +/À additional immunosuppressants (e.g., infliximab, mycophenolate, and vedolizumab). Consider PJP prophylaxis in patients with prolonged corticosteroid exposure [33, 73] 14 ICANS: Median onset 4 days (1-43 days); median duration of neurologic toxicities 17 days. Most common neurological toxicities: encephalopathy, headache, tremor, dizziness, aphasia, delirium, insomnia, and anxiety. Fatal and serious cases of cerebral edema have occurred. Other serious events included leukoencephalopathy and seizures CRS: Median onset 2 days (1-12 days); median duration 7 days (2-58 days) . Key manifestations of CRS: fever, hypotension, tachycardia, hypoxia, and chills Management of CRS depends on grading or severity but includes supportive care, interleukin-2 receptor antagonist tocilizumab, and/or systemic corticosteroids Grade 2 or higher ICANS without CRS should be treated with supportive care and/or systemic corticosteroids as there is insufficient data with tocilizumab in this setting. Consider anti-seizure medicines (e.g., levetiracetam) for seizure prophylaxis for any grade 2 or higher neurologic toxicities Cardiac arrhythmias (e.g., atrial fibrillation, ventricular tachycardia), cardiac arrest, cardiac failure, renal insufficiency, capillary leak syndrome, HLH/MAS can occur Hypogammaglobulinemia secondary to B-cell aplasia may persist for up to 13 months and increase the risk for infections. PJP and HSV prophylaxis is recommended for at least 1 year after CAR-T cell therapy [128, 161, 221] 15 Wound healing complications -hold for at least 24 h prior to surgery and restart when wound healed. RPLS is rare but serious. Monitor for headache, seizure, lethargy, and hypertension [187] 16 QT prolongation is a class effect of HDAC inhibitors, although the incidence may be lower than initially reported. Optimize serum potassium and magnesium levels [205, 228] 17 Severe cutaneous reactions including SJS, TEN, DRESS, and bullous pemphigoid have been reported [45, 131, 239] 18 RPLS: onset of symptoms from 16 h to 1 year after the first dose. Monitor for headache, seizure, lethargy, and hypertension. Wound healing: if possible wait at least 4 weeks after bevacizumab discontinuation for major surgical procedures and do not restart for at least 4 weeks after surgery or until wound is fully healed. Cases of TMA have been reported. Higher incidence of GI perforation in patients with previous pelvic irradiation. Severe pulmonary hemorrhage reported in NSCLC [30, 75, 87, 107, 197 New onset or exacerbation of HF, pneumonitis, and pulmonary hypertension may occur. Acute liver failure and RPLS have been reported rarely with bortezomib. HSV/VZV prophylaxis is required during therapy due to risk of reactivation [150] 23 Most common toxicities are GI (i.e., diarrhea, nausea, and vomiting). Pleural effusions may develop in patients with a prior history of pleural effusions and dasatinib exposure [125] 24 Serious and fatal cases of GI complications (i.e., acute pancreatitis, hemorrhage, obstruction, perforation) and hepatotoxicity have been reported, with higher incidence in patients with GI or liver disease involvement. Cases of PML and death due to JC virus infection have occurred with median onset of 7 weeks after initiation (3-34 weeks) ( [48] , Seattle [217] ) 25 Symptomatic bradycardia can occur. When treating hypertension, use caution when administering with antihypertensive agents that can cause bradycardia. Higher incidence and earlier onset of pneumonitis compared to other ALK inhibitors. ILD/pneumonitis typically occurs within 9 days of initiation -higher incidence with 180 mg/day vs 90 mg/day. Monitor CPK at baseline and periodically for signs or symptoms of muscle pain or weakness [9, 127] . 26 Anti-seizure prophylaxis required with administration of busulfan. VOD is a risk among patients receiving busulfan, but the incidence has decreased since the transition in standard of care from oral to IV busulfan and the use of PK for dosing. Avoid use of acetaminophen, metronidazole, or introduction of any medication that may inhibit/induce CYPA3A4 for at least 72 h before, during, and for 72 h after busulfan administration as these are major drug interactions that will affect PK dosing [52, 181] 27 Case reports of hemorrhagic cystitis, which may be due to radiation recall in patients with history of pelvic irradiation. High rates of grade 3/4 neutropenia in clinical trials [97, 141, 213] 28 RPLS has occurred rarely in trials. Monitor for headache, seizure, lethargy, and hypertension. Can impair wound healing -hold 28 days prior to surgery and resume once wound has healed [76] Infusion-related reactions including bronchospasm, pneumonitis, and pulmonary edema may occur. Combination regimens with corticosteroids and premedication with antihistamines and antipyretics have helped alleviate symptoms, although patients may still be at risk for delayed infusion reactions. Consider bronchodilators in patients with a history of COPD or FEV 1 < 80%.

HSV prophylaxis should start within 1 week of initiation and continue for 3 months following treatment. May result in a false-positive Indirect Coombs test that may persist for up to 6 months after the last infusion [111] 47

Optimize serum potassium and magnesium levels prior to and during therapy to reduce risk of cardiotoxicity. Pleural effusions can occur. Management of pleural effusions consists of temporary dose interruption, dose reductions, diuretics, and/or corticosteroids. Pulmonary arterial hypertension typically occurs after 8-48 months of exposure. Increased risk of bleeding in those with advanced disease and thrombocytopenia [28, 39, 55, 134, 152, 194, 220] 48

Onset of cardiotoxic effects of anthracyclines can occur during or immediately after infusion (acute onset), within 1 year of exposure (early onset), and from 1-20 years (late onset) after initial exposure. Factors increasing the risk of cardiac toxicity include the extent of anthracycline exposure, higher doses, older age, pre-existing cardiac disease, concurrent or previous mediastinal radiation therapy, and concomitant administration of cardiotoxic chemotherapy regimens such as paclitaxel or trastuzumab. The incidence of cardiac toxicity increases after a total cumulative dose exceeding 400-550 mg/m 2 in adults, 300 mg/m 2 in children more than 2 years of age, or 10 mg/kg in children less than 2 years of age [27] 49 Cardiotoxicity may occur due to the anthracycline component (daunorubicin) of the formulation. Observe the same risk factors for cardiotoxicity as with conventional anthracyclines. This formulation is not interchangeable with other formulations of daunorubicin and cytarabine [114, 132] The risk of CVA is increased in patients with pancreatic cancer, with a higher incidence found in those receiving erlotinib + gemcitabine (2.5%) versus gemcitabine alone. Median onset of ILD symptoms is 39 days (5 days to more than 9 months) after initiating therapy. Renal failure may arise from exacerbation of underlying baseline hepatic impairment or severe dehydration. Rare incidence of renal failure in monotherapy (0.5%) and Cardiopulmonary arrest and/or sudden death has been reported in patients treated with necitumumab in combination with gemcitabine and cisplatin. Severe hypomagnesemia is common in those treated with necitumumab, gemcitabine, and cisplatin, with a median onset of 6 weeks. Optimize serum potassium, magnesium, and calcium during and for at least 8 weeks following administration. Cerebral stroke and MI have also been reported [68, 240] 87 Most neurologic toxicities occur within 12 days of infusion or after successive cycles of therapy. The most common grade 3/4 neurologic adverse events reported include confusion, malaise, somnolence, ataxia, muscle weakness, and peripheral neuropathies [121, 130] 88 Risk of QT prolongation warrants a baseline 12-lead EKG with repeat assessment after 7 days of therapy, following any dose change, and regularly during treatment. Optimize serum potassium and magnesium levels prior to and during therapy. Biochemical abnormalities are common (i.e., increased lipase, glucose, total bilirubin, ALT) [4, 94, 103, 135, 172, 198] 89 Hypertensive crisis has been reported [237] 90 May cause severe immune-mediated adverse events including pneumonitis, median onset 1.6-3. [29, 162] 97 [191] 98

Monitor for hypomagnesemia and hypocalcemia prior to, during and up to 8 weeks after therapy. Severe dermatologic complications may effect up to 15% of patients and can lead to lifethreatening infectious complications such as necrotizing fasciitis and abscesses [8, 179] 99 QT prolongation is a class effect of HDAC inhibitors, although the incidence may be lower than initially reported. Optimize serum potassium and magnesium levels prior to and during therapy [173, 205] 100 RPLS is rare but serious. Monitor for headache, seizure, lethargy, and hypertension. Some fatal cases of hepatotoxicity have been reported. Serum hepatic enzyme elevations generally occur within 4-12 weeks. The most common hemorrhagic events were hematuria (4%), epistaxis (2%), hemoptysis (2%), and rectal hemorrhage. Rare cases of hypertensive crisis have been reported, most cases of hypertension within first 18 weeks of therapy. TMA including TTP and HUS can occur, generally within 3 months of treatment initiation [136, 158, 166, 209] 101 Complications typically occur after several weeks of treatment during the induction phase. Clinical symptoms suggestive of pancreatitis have been reported to occur within 15 days of treatment [65] 102 May cause severe immune-mediated adverse events including pneumonitis median onset 3.3 months (2 days to~19 months) and is more common with prior thoracic radiation, hepatitis 1.3 months (8 days to 21.4 months), colitis 3.5 months (10 days to 16.2 months), autoimmune nephritis 5.1 months (12 days to 12.8 months), hyperthyroidism 1.4 months (1 day tõ 22 months), and hypothyroidism 3.5 months (1 day to 19 months). May aggravate underlying autoimmune disorders. Management includes holding therapy, systemic corticosteroids, and +/À additional immunosuppressants (e.g., infliximab, mycophenolate, and vedolizumab). Consider PJP prophylaxis in patients with prolonged corticosteroid exposure [33, 148, 159, 160] 103 Prophylactic folic acid and vitamin B12 supplementation should be provided while receiving pemetrexed to reduce the risk of hematologic toxicity. Renal damage ranges from acute to chronic kidney injury due to tubular and interstitial damage [70, 252] 104 Consider HSV/VZV prophylaxis [105, 142] 105 Prior anthracycline therapy or chest irradiation may increase the risk for cardiotoxicity (risk is lower than that seen with trastuzumab) [83, 235] 106 Thromboprophylaxis with either aspirin or a LMWH should be considered for patients receiving pomalidomide in combination with chemotherapy and/or dexamethasone [49, 92] . 107 Vigilant monitoring for vascular events is recommended (i.e., MI, stroke, stenosis of large arterial vessels of the brain, severe peripheral vascular disease). Vascular occlusion/events can occur within weeks of starting therapy and is not dose dependent and requires interruption or permanent discontinuation of therapy. Arrhythmias, such as atrial fibrillation and symptomatic bradycardia, have been reported. Hypertension can be severe and should be managed as clinically indicated. Hepatotoxicity: median onset 3 months (range, less than 1 month to 47 months); may require treatment interruption or discontinuation. Bleeding can occur during therapy, particularly in patients with accelerated or blast phase disease and thrombocytopenia. RPLS has been reported. Monitor for headache, seizure, lethargy, and hypertension [53, 54, 139, 155, 247] Median time to PML diagnosis 16 months following rituximab initiation and median time from last rituximab dose 5.5 months. HBV reactivation may occur during and up to 24 months after discontinuation of anti-CD20 antibodies. Patients on antiviral prophylaxis should continue for 6-12 months after completing treatment [32, 47, 106] 113 QT prolongation is a class effect of HDAC inhibitors, although the incidence may be lower than initially reported. Optimize serum potassium, magnesium, and calcium levels prior to and during therapy. Viral reactivation has occurred during and within 30 days of initiation. Consider antiviral prophylaxis for patients with history of EBV or HBV [50, 205] 114 Bacterial, mycobacterial, fungal, and viral infections have occurred including TB, PML, HSV/VZV and increased HBV viral load. Withdrawal syndrome can occur with abrupt discontinuation of treatment and is characterized by acute relapse of disease symptoms such as accelerated splenomegaly, worsening cytopenias, and sepsis-like syndrome. It can be managed with corticosteroids with a slow taper off [108] 115 Vascular disorders including MI and stroke have been reported. Acute infusion reactions within 1 day of infusion have been reported [61] . 116 CPK elevations > grade 2 occur at a median of 13 weeks. CPK levels should be monitored at baseline and periodically during therapy. Rare cases of rhabdomyolysis have been reported [110, 233] Differentiation syndrome is commonly associated with the development of hyperleukocytosis, pulmonary edema, generalized edema, headache, bone pain, and renal failure; bimodal with peaks occurring in the first and third weeks after the start of therapy. Management includes steroids, with or without diuretics, and possible discontinuation of tretinoin, depending on severity [59, 153] 128 Ischemic cerebrovascular events have been reported. RPLS has been reported -monitor for headache, seizure, lethargy, and hypertension. Optimize serum potassium, magnesium, and calcium levels prior to and during therapy. Rare cases of GI perforation. Due to long half-life (19 days), adverse reactions, including QT prolongation, may resolve slowly [214, 254] 129 Optimize serum potassium, magnesium, and calcium levels prior to and during therapy to reduce risk of cardiotoxicity. AIN and ATN have been reported. Hypersensitivity: anaphylaxis and DRESS syndrome have been reported. Pancreatitis generally occurs within 2 weeks of treatment initiation [90, 157, 251, 255, 256] 130 Paralytic ileus and obstruction may occur, although to a lesser extent than that observed with other vinca alkaloids 131 Known to affect the cranial nerves resulting in ptosis, diplopia, and facial palsies. Paresthesias involving the hands and feet often occur within weeks of therapy and depending on severity and may require several months to resolve following drug discontinuation. Loss of motor involvement is possible as well (i.e., foot and hand drop, loss of deep tendon reflexes, weakness in the lower and upper extremities). Acute GI symptoms such as constipation and abdominal pain commonly occur within a few days of therapy, with more serious GI toxicities including adynamic ileus and bowel obstruction. SIADH-induced hyponatremia has led to seizures [200] 132 May cause severe paralytic ileus [44, 188] 133 May cause CPK elevations; rare occurrence of rhabdomyolysis [88] 134 QT prolongation is a class effect of HDAC inhibitors, although the incidence may be lower than initially reported. Optimize serum potassium and magnesium levels prior to and during therapy [205] MAS, macrophage activation syndrome; MI, myocardial infarction; NSCLC, non-small cell lung cancer; PD-1, programmed cell death 1; PJP, Pneumocystis jiroveci pneumonia; PK, pharmacokinetics; PML, progressive multifocal leukoencephalopathy; REMS, risk evaluation and mitigation strategy; RPLS, reversible posterior leukoencephalopathy syndrome; SJS, Stevens-Johnson syndrome; TB, tuberculosis; TBI, total body irradiation; TEN, toxic epidermal necrolysis; TMA, thrombotic microangiopathy; TSH, thyroid-stimulating hormone; TTP, thrombotic thrombocytopenic purpura; ULN, upper limit of normal; VOD, veno-occlusive disease; VTE, venous thromboembolism; VZV, varicella zoster virus

Abraxane (paclitaxel protein-bound particles) [package insert

Accord Healthcare Inc. Toposar (etoposide) [package insert

Atypical Pneumocystis jirovecii pneumonia in previously untreated patients with CLL on single-agent ibrutinib

Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML

Toxicity profile of repeated doses of PEG-asparaginase incorporated into a pediatric-type regimen for adult acute lymphoblastic leukemia

Folotyn (pralatrexate) [package insert

Thousand Oaks

Thousand Oaks

Metaanalysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab

Hepatic veno-occlusive disease due to DTIC

Imfinzi (durvalumab) [package insert]. Wilmington; 2016. 13. AstraZeneca Pharmaceuticals. Calquence (acalabrutinib) [package insert

Lynparza (olaparib) capsules [package insert

Ceritinib: a primer for pharmacists

Bleomycin lung toxicity: who are the patients with increased risk?

Iressa (gefitinib) [package insert

Cytarabine and neurologic toxicity

Fungal infections in patients treated with ibrutinib: two unusual cases of invasive aspergillosis and cryptococcal meningoencephalitis

Cyclophosphamide Injection [package insert

Ifex (ifosfamide) [prescribing information

Nexevar (sorafenib) [package insert

Bayer HealthCare Pharmaceuticals Inc. Stivarga (regorafenib) [package insert

Adriamycin (doxorubicin HCL) [package insert

Daunorubicin hydrochloride injection

Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series

Paclitaxel-induced pneumonitis in patients with breast cancer: case series and review of the literature

Thrombotic microangiopathy with targeted cancer agents

Gilotrif (afatinib) [package insert

Progressive multifocal leukoencephalopathy and monoclonal antibodies: a review

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline

Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American society of clinical oncology clinical practice guideline

Ixempra (ixabepilone) [package insert

Opdivo (nivolumab) [package insert

Blenoxane (bleomycin) [package insert

Platinol (cisplatin) [package insert

Sprycel (dasatinib) [package insert

Yervoy (ipilimumab) [package insert

Acalabrutinib (ACP-196) in Relapsed Chronic Lymphocytic Leukemia

CTLA-4 blockade with ipilimumab: biology, safety, efficacy, and future considerations

Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD

Syndrome of inappropriate antidiuretic hormone secretion (SIADH) induced by vinorelbine treatment of metastatic breast cancer

Severe dermatologic reactions with bendamustine: a case series

Gemcitabine-associated diffuse alveolar hemorrhage

Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project

Progressive multifocal leukoencephalopathy associated with brentuximab vedotin therapy: a

Pomalyst (pomalidomide) [package insert

Istodax (romidepsin) [package insert

Thalomid (thalidomide) [package insert

Busulfan in hematopoietic stem cell transplantation

Ponatinib in refractory Philadelphia chromosome-positive leukemias

A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias

Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naive chronic myeloid leukemia patients trial

Reversible posterior encephalopathy syndrome secondary to sunitinib

Large bowel perforation associated with capecitabine treatment for breast cancer

Hepatic veno-occlusive disease after hematopoietic stem cell transplantation: risk factors and stratification, prophylaxis, and treatment

Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group

Cardiotoxicity of high-dose continuous infusion fluorouracil: a prospective clinical study

Provenge (sipuleucel-T) [package insert

Cyclophosphamide-induced cardiomyopathy: a case report, review, and recommendations for management

Cardiac and renal complications of carfilzomib in patients with multiple myeloma

Efficacy and safety of olaparib monotherapy in germline BRCA1/2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy

Pharmacokinetics-based integration of multiple doses of intravenous pegaspargase in a pediatric regimen for adults with newly diagnosed acute lymphoblastic leukemia

High dose interleukin-2 (Aldesleukin) -expert consensus on best management practices

Lenvima (lenvatinib) capsules [package insert

Bavencio (avelumab)

Novantrone (Mitoxantrone) [package insert

VEGF inhibition and renal thrombotic microangiopathy

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

Cerebrovascular complications of L-asparaginase therapy

Gastrointestinal perforations in patients treated with erlotinib: a report of two cases with fatal outcome and literature review. Lung Cancer (Amsterdam, Netherlands)

Adverse effects of intrathecal methotrexate in children with acute leukemia in remission

Herceptin (trastuzumab)

Kadcyla (ado-traztuzumab emtansine)

Perjeta (pertuzumab)

Xeloda (capecitabine)

Alecensa (alectinib) [package insert] South San Francisco

Erivedge (vismodegib)

Tecentriq (atezolizumab)

Zelboraf (vemurafenib)

Genzyme Corporation. Lemtrada (alemtuzumab)

Acute lung toxicity related to pomalidomide

Gilead Sciences. Zydelig (idelalisib)

Rates of peripheral arterial occlusive disease in patients with chronic myeloid leukemia in the chronic phase treated with imatinib, nilotinib, or non-tyrosine kinase therapy: a retrospective cohort analysis

Alkeran ® (melphalan) [package insert

The temporal risk of heart failure associated with adjuvant trastuzumab in breast cancer patients: a population study

Hemorrhagic cystitis in patients treated with cabazitaxel: a radiation recall syndrome?

Thyroid dysfunction from antineoplastic agents

L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease

Fludarabine-related pulmonary toxicity: a distinct clinical entity in chronic lymphoproliferative syndromes

BiCNU (carmustine) [package insert

Cerebellar toxicity with high-dose cytosine arabinoside

Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial

Ribociclib as first-line therapy for HR-positive, advanced breast cancer

Lake Forest

Hepatitis B virus screening for patients with cancer before therapy: American society of clinical oncology provisional clinical opinion update

Diffuse alveolar hemorrhage as a fatal adverse effect of bevacizumab: an autopsy case

Jakafi (ruxolitinib) [package insert]. Wilmington

Ingenus Pharmaceuticals. Carboplatin [package insert

Sonidegib: mechanism of action, pharmacology, and clinical utility for advanced basal cell carcinomas

Darzalex (daratumumab) [package insert

Yondelis (trabectedin) [package insert

Janssen Products. Doxil (doxorubicin HCl liposome injection) [package insert]. Horsahm

VYXEOS (daunorubicin and cytarabine) liposome [package insert

Erwinaze intramuscular injection, intravenous injection (asparaginase Erwinia chrysanthemi intramuscular injection, intravenous injection) [package insert

Fulminant myocarditis with combination immune checkpoint blockade

Ibritumomab tiuxetan for non-Hodgkin's lymphoma

Clustering of adverse drug events: analysis of risk factors for cerebellar toxicity with high-dose cytarabine

Juno Therapeutics and Celgene corporation release additional data from TRAN-SCEND trial of JCAR017 in patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Everolimus-induced severe pulmonary toxicity with diffuse alveolar hemorrhage

Nelarabine in the treatment of pediatric and adult patients with T-cell acute lymphoblastic leukemia and lymphoma

Two cases of atezolizumab-induced hypophysitis

Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Feasibility of allografting in patients with advanced acute lymphoblastic leukemia after salvage therapy with inotuzumab ozogamicin

Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failure

Cerebrovascular complications of L-asparaginase in the therapy of acute lymphoblastic leukemia

Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial

Kite Pharma Inc. Yescarta (axicabtagene ciloleucel)

Carboxypeptidase-G2 rescue in cancer patients with delayed methotrexate elimination after high-dose methotrexate therapy

Neurotoxic side effects in children with refractory or relapsed T-cell malignancies treated with nelarabine based therapy

Stevens-Johnson syndrome after treatment with bendamustine

Abstract 7000) Final results of a phase III randomized trial of CPX-351 versus 7+3 in older patients with newly diagnosed high risk (secondary) AML

Combined Nivolumab and ipilimumab or monotherapy in untreated melanoma

Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia

Severe peripheral arterial disease during nilotinib therapy

Overview and management of cardiac adverse events associated with tyrosine kinase inhibitors

Verzenio (abemaciclib) [package insert

Mitomycininduced pulmonary toxicity: case report and review of the literature

Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Venous thromboembolism prophylaxis and treatment in patients with cancer: American society of clinical oncology clinical practice guideline update

CT findings in patients with Cabazitaxel induced pelvic pain and haematuria: a case series

Clinical features of hypersensitivity reactions to carboplatin

Tisagenlecleucel in children and young adults with B-Cell Lymphoblastic Leukemia

Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project

Ibrutinib increases the risk of atrial fibrillation, potentially through inhibition of cardiac PI3K-Akt signaling

Temodar (temozolomide)

Whitehouse Station

Keytruda (pembrolizumab)

Whitehouse Station

Symptomatic cardiotoxicity associated with 5-fluorouracil

Acute hyperammonemic encephalopathy after fluoropyrimidine-based chemotherapy: a case series and review of the literature

Pulmonary arterial hypertension in patients treated by dasatinib

Differentiation syndrome in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline chemotherapy: characteristics, outcome, and prognostic factors

Oxaliplatininduced pulmonary toxicity in gastrointestinal malignancies: two case reports and review of the literature

Tyrosine Kinase Inhibitor-Associated Cardiovascular Toxicity in Chronic Myeloid Leukemia

Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma

Early-onset vemurafenib-induced DRESS syndrome

Reversible posterior leukoencephalopathy syndrome during regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Pneumonitis in patients treated with anti-programmed death-1/programmed death ligand 1 therapy

Axicabtagene ciloleucel CAR T-Cell therapy in refractory large B-Cell lymphoma

Neutropenic enterocolitis, a growing concern in the era of widespread use of aggressive chemotherapy

A to Z list of cancer drugs

Afinitor and Afinitor Disperz (everolimus)

East Hanover

Votrient (pazopanib) [package insert

Novartis Pharmaceutical Co. Zykadia (ceritinib) [package insert] East Hanover

Hycamtin (topotecan oral capsules) [package insert

Mekinist (trametinib) [package insert

Tafinlar (dabrafenib) [package insert

Novartis Pharmaceuticals. Tasigna oral capsules, nilotinib oral capsules

Kymriah (tisagenlecleucel) [prescribing information

Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate

Disseminated cryptococcal disease in a patient with chronic lymphocytic leukemia on ibrutinib

Mitomycin lung toxicity. Acute and chronic phases

Clinical features and risk factors of panitumumab-induced interstitial lung disease: a postmarketing all-case surveillance study

OSI Pharmaceuticals L, an affiliate of Astellas Pharma US, Inc. Tarceva (erlotinib)

Cosmegen (dactinomycin) [package insert

Methylene blue for management of Ifosfamide-induced encephalopathy

Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials

Lapatinib-induced hepatitis: a case report

Clofarabineassociated acute kidney injury in patients undergoing hematopoietic stem cell transplant

Inlyta (axitinib) [package insert

Research Triangle Park

Sutent (sunitinib) [package insert

Xalkori (crizotinib)

Ibrance (palbociclib)

Imbruvica (ibrutinib) [package insert

Dasatinib 100 mg once daily minimizes the occurrence of pleural effusion in patients with chronic myeloid leukemia in chronic phase and efficacy is unaffected in patients who develop pleural effusion. Cancer

Leukeran (chlorambucil) [package insert

Bevacizumab increases the risk of severe congestive heart failure in cancer patients: an up-to-date meta-analysis with a focus on different subgroups

Nilotinib-associated vascular events. Clin Lymphoma Myeloma Leuk

Severe interstitial pneumonitis associated with docetaxel administration

Vincristine neurotoxicity and abnormal secretion of antidiuretic hormone

Prevalence, management, and clinical consequences of QT interval prolongation during treatment with arsenic trioxide

Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs

Managing treatmentrelated adverse events associated with Alk inhibitors

Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer

Electrocardiographic effects of class 1 selective histone deacetylase inhibitor romidepsin

Hemolytic-uremic syndrome associated with gemcitabine: a case report and review of literature

Capecitabine-related cardiotoxicity: recognition and management

Chlorambucilinduced seizures

Management of toxicities with pazopanib in advanced soft tissue sarcoma

Zaltrapt (afilibercept) [package insert

Eloxatin (oxaliplatin) [package insert

Caprelsa (vandetanib)

How we prevent and treat differentiation syndrome in patients with acute promyelocytic leukemia

Cardiac toxicity of sunitinib and sorafenib in patients with metastatic renal cell carcinoma

Adcetris (brentuximab vedotin) [package insert

Clinical features and outcomes of posterior reversible encephalopathy syndrome following bevacizumab treatment

Invasive fungal sinusitis due to Mucor species in a patient on ibrutinib

Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia

Chimeric Antigen Receptor T Cells in Hematologic Malignancies

Delayed reversible posterior encephalopathy syndrome following chemotherapy with oxaliplatin

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer

Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse

MONARCH 2: abemaciclib in combination with fulvestrant in women with HR+/HER2-advanced breast cancer who had progressed while receiving endocrine therapy

High-dose cytarabine dose modification reduces the incidence of neurotoxicity in patients with renal insufficiency

First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study

Cisplatin-induced encephalopathy and seizures. Anti-Cancer Drugs

Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia

Corticosteroid responsive fludarabine pulmonary toxicity

Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412

Odomzo (sonidegib) [package insert

Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in CLEOPATRA: a randomized, double-blind, placebo-controlled phase III study

Optimizing bexarotene therapy for cutaneous T-cell lymphoma

Zejula (niraparib)

Adrucil (fluorouracil injection)

Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line therapy in patients with stage IV squamous nonsmall-cell lung cancer (SQUIRE): an open-label, randomised

Hypersensitivity pneumonitis-like syndrome associated with the use of lenalidomide

Long-term followup of hematologic relapse-free survival in a phase 2 study of blinatumomab in patients with MRD in B-lineage all

Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia

Interstitial lung disease associated with gemcitabine treatment in patients with non-small-cell lung cancer and pancreatic cancer

Unituxin (dinutuximab) [package insert]. Silver Spring

Infiltrative lung diseases: complications of novel antineoplastic agents in patients with hematological malignancies

Vascular safety issues in CML patients treated with BCR/ABL1 kinase inhibitors

Prospective study on the dose relationship of mitomycin C-induced interstitial pneumonitis. Cancer

Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation

Renal toxicities of novel agents used for treatment of multiple myeloma

Renal effects of BRAF inhibitors: a systematic review by the cancer and the Kidney International Network

Pemetrexed-Induced Interstitial pneumonitis: a case study and literature review

The nitrosoureas and pulmonary toxicity

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

Vemurafenib-induced DRESS

ESC position paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC committee for practice guidelines